Dynamic Technology Lab Private Ltd acquired a new stake in Ingevity Co. (NYSE:NGVT – Free Report) during the third quarter, Holdings Channel reports. The firm acquired 23,530 shares of the company’s stock, valued at approximately $918,000.
Other institutional investors have also added to or reduced their stakes in the company. First Horizon Advisors Inc. raised its position in shares of Ingevity by 809.2% in the second quarter. First Horizon Advisors Inc. now owns 591 shares of the company’s stock valued at $26,000 after purchasing an additional 526 shares during the period. Isthmus Partners LLC bought a new stake in Ingevity during the 2nd quarter valued at $35,000. Blue Trust Inc. lifted its position in shares of Ingevity by 101.8% during the second quarter. Blue Trust Inc. now owns 896 shares of the company’s stock worth $43,000 after acquiring an additional 452 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Ingevity in the second quarter worth $46,000. Finally, KBC Group NV grew its position in shares of Ingevity by 50.8% in the third quarter. KBC Group NV now owns 1,574 shares of the company’s stock valued at $61,000 after purchasing an additional 530 shares in the last quarter. 91.59% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research analysts have commented on NGVT shares. Wells Fargo & Company cut their target price on Ingevity from $45.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, August 5th. CJS Securities raised shares of Ingevity from a “market perform” rating to an “outperform” rating and set a $58.00 price target on the stock in a report on Wednesday, August 7th. BMO Capital Markets boosted their price objective on shares of Ingevity from $40.00 to $47.00 and gave the company a “market perform” rating in a research note on Thursday, October 31st. Finally, Oppenheimer lowered their target price on shares of Ingevity from $58.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, August 1st. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $52.17.
Ingevity Stock Up 0.5 %
Shares of NYSE NGVT opened at $47.73 on Thursday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 6.52. Ingevity Co. has a 12 month low of $30.90 and a 12 month high of $56.29. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -3.07 and a beta of 1.60. The business has a 50-day moving average of $39.98 and a 200-day moving average of $41.85.
Ingevity (NYSE:NGVT – Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.50. The firm had revenue of $376.90 million during the quarter, compared to analysts’ expectations of $376.95 million. Ingevity had a positive return on equity of 24.46% and a negative net margin of 38.11%. The company’s revenue for the quarter was down 15.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.21 EPS. Sell-side analysts expect that Ingevity Co. will post 2.55 earnings per share for the current fiscal year.
Ingevity Profile
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.
Recommended Stories
- Five stocks we like better than Ingevity
- Business Services Stocks Investing
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How is Compound Interest Calculated?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Want to Profit on the Downtrend? Downtrends, Explained.
- 2 Generic Drug Stocks Ready to Surge in 2025
Want to see what other hedge funds are holding NGVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ingevity Co. (NYSE:NGVT – Free Report).
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.